These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 30407350)

  • 1. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
    Yasuoka S; Hamasaki T; Kuribayashi E; Nagasawa M; Kawaguchi T; Nagashima Y; Kondo Y
    Medicine (Baltimore); 2018 Nov; 97(45):e13173. PubMed ID: 30407350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T; Iijima K; Kusama Y; Otsuki T; Kato H
    J Med Case Rep; 2022 May; 16(1):193. PubMed ID: 35581611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage ipilimumab associated with a significant response in sarcomatoid renal cell carcinoma.
    George G; Schmidt L; Tolat P; Riese M; Kilari D
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab.
    Tomioka M; Nakane K; Ozawa K; Iinuma K; Suzui N; Miyazaki T; Koie T
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1356. PubMed ID: 33656804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1-positive primary lung squamous cell carcinoma responded very well to ICI therapy: a case report.
    Urushibara M; Ishizaka K; Matsutani N; Takahashi M; Nagata M; Okumura T; Matsumoto Y; Tatsuoka S; Nenohi T; Amemiya T; Shimizu Y; Shirakawa T; Kato D
    World J Surg Oncol; 2023 Feb; 21(1):37. PubMed ID: 36747242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.
    Milowsky MI; Rosmarin A; Tickoo SK; Papanicolaou N; Nanus DM
    Cancer; 2002 Jan; 94(1):111-6. PubMed ID: 11815966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].
    Kullmann T; Pintér T; Szepesvári Z; Kránitz N; Culine S
    Orv Hetil; 2016 Mar; 157(11):436-9. PubMed ID: 26947093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
    Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
    Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
    Mizutani K; Horie K; Nagai S; Tsuchiya T; Saigo C; Kobayashi K; Miyazaki T; Deguchi T
    Mol Clin Oncol; 2017 Dec; 7(6):988-990. PubMed ID: 29285361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
    Staehler M; Haseke N; Schöppler G; Stadler T; Karl A; Siebels M; Ihrler S; Stief CG
    Eur J Med Res; 2008 Nov; 13(11):531-5. PubMed ID: 19073390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A renal cancer with intermediate characteristics between collecting (Bellini) duct carcinoma and urothelial carcinoma: case report and review of the literature.
    Maestroni U; Ferretti S; Dinale F; Froio E; Pilato FP; Ciuffreda M; Mellissari M; Cortellini P
    Tumori; 2006; 92(6):545-8. PubMed ID: 17260499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
    Staehler M; Schöppler G; Haseke N; Stadler T; Karl A; Siebels M; Ihrler S; Stief CG
    Clin Genitourin Cancer; 2009 Jan; 7(1):58-61. PubMed ID: 19213670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
    Zhao RN; Nie LH; Gong R; Wang JZ; Wazir R; Liu LR; Song TR; Wei Q
    Int Urol Nephrol; 2013 Aug; 45(4):1017-21. PubMed ID: 23686671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Complete Remission of Metastatic Renal Cell Carcinoma with Invasion of the Duodenum and Pancreas after Treatment with Nivolumab Plus Ipilimumab Followed by Axitinib and Surgery : A Case Report].
    Hagimoto H; Yamazaki T; Kashima S; Yoshino T; Goto T; Sano T; Sawada A; Akamatsu S; Kobayashi T; Nakano K; Yagi S; Matsuoka Y; Fujimoto M; Kitamura T; Ogawa O
    Hinyokika Kiyo; 2021 May; 67(5):197-203. PubMed ID: 34126663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of cabozantinib in radioresistant brain metastases from renal cell carcinoma: two case reports.
    Négrier S; Moriceau G; Attignon V; Haddad V; Pissaloux D; Guerin N; Carrie C
    J Med Case Rep; 2018 Nov; 12(1):351. PubMed ID: 30474572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case of complete response to neoadjuvant therapy using nivolumab in a patient with metastatic renal cell carcinoma.
    Ikarashi D; Kato Y; Katagiri H; Takahara T; Uesugi N; Shiomi E; Sugimura J; Nitta H; Sugai T; Obara W
    Int J Urol; 2018 Jun; 25(6):630-632. PubMed ID: 29693280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
    Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
    Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
    Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
    Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
    Pécuchet N; Bigot F; Gachet J; Massard C; Albiges L; Teghom C; Allory Y; Méjean A; Escudier B; Oudard S
    Ann Oncol; 2013 Dec; 24(12):2963-7. PubMed ID: 24190963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.